<DOC>
	<DOCNO>NCT02121769</DOCNO>
	<brief_summary>Omegaven intravenous fat emulsion ( IFE ) comprise omega-3 fatty acid derive fish oil . It use open label compassionate use treatment protocol , alternative soybean oil ( omega-6 ) , sole IFE source parenteral nutrition effort reduce and/or reverse parenteral nutrition associate liver disease . The study evaluate safety efficacy Omegaven use pediatric patient PN dependence PNALD .</brief_summary>
	<brief_title>Omegaven Expanded Access Protocol</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Patients PN dependent ( unable meet nutritional need solely enteral nutrition ) expect require PN least another 30 day Parenteral nutrition associate liver disease ( PNALD ) define direct bilirubin â‰¥ 2 mg/dL last two consecutive bilirubin PN . Other cause liver disease exclude . A liver biopsy necessary treatment . Failed standard/conventional therapy prevent progression PNALD . Age newborn 17 year age Signed informed consent . Allergy eggs and/or shellfish Female pregnant lactate Severe hemorrhagic disorder Other cause chronic liver disease ( Hepatitis C , Cystic fibrosis , biliary atresia , alpha 1 antitrypsin deficiency , ) 18 year age old Parent/legally authorize representative unwilling consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>cholestasis</keyword>
	<keyword>short bowel syndrome</keyword>
</DOC>